Novo Nordisk's Triple-G Agonist Clears Midphase Diabetes Trial, Keeping Pressure on Lilly
By FieldPulse Editorial · March 25, 2026
Tags: GLP-1, Clinical Trials, Pipeline
Novo Nordisk's triple-G agonist — targeting GLP-1, GIP, and glucagon receptors — has produced competitive results in a midphase diabetes trial, adding to an intensifying post-semaglutide rivalry with Eli Lilly in the next-generation metabolic class.
Novo Nordisk's triple-G agonist, a next-generation metabolic drug targeting GLP-1, GIP, and glucagon receptors simultaneously, has cleared a midphase diabetes trial in China with competitive results, the company announced Wednesday.
The data add another data point to one of the most consequential races in pharmaceutical development: who follows semaglutide, and with what.
Triple-G agonists represent a step beyond the dual-agonist class that Eli Lilly currently leads with tirzepatide.
By adding glucagon receptor activation to the GLP-1 and GIP combination, these drugs aim to drive additional metabolic effects — potentially including greater weight loss and improved glucose control — compared to existing agents.
The science is still being established, but the rationale has generated significant industry and investor attention.
Lilly has a recognized development lead in the triple-G class, but Novo Nordisk's midphase results demonstrate that the company is advancing its own candidate with credible clinical data.
The China trial setting reflects the global nature of this competition and the regulatory strategy of running studies in large patient populations that can support filings in multiple markets.
The GLP-1 space has transformed the pharma industry's commercial and pipeline priorities at a speed rarely seen.
What began as a diabetes drug category has expanded into obesity, cardiovascular disease, metabolic dysfunction-associated steatohepatitis, and a range of other indications, generating some of the highest-revenue products in pharmaceutical history.
Both Novo Nordisk and Lilly have staked enormous commercial and scientific resources on staying at the frontier of this category.
For reps carrying GLP-1 or metabolic products — or competing against them — the triple-G data is relevant context.
The next generation of this drug class is in active development, and the competitive dynamics between Novo and Lilly at the pipeline level will eventually translate into new o.
Source: https://www.fiercebiotech.com/